Phase I Trial of Programmed Allogeneic CRISPR-edited T cells (PACE) Gene Edited to Eliminate Endogenous TCR HLA-class I and HLA-class II and Engineered to Express anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Phase I Trial of Programmed Allogeneic CRISPR-edited T cells (PACE) Gene Edited to Eliminate Endogenous TCR HLA-class I and HLA-class II and Engineered to Express anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Recruiting
18 years - 99 years
All
Phase 1
36 participants needed
1 Location

Brief description of study

This research study is being conducted to evaluate an experimental drug called PACE CART19 in patients with leukemia or lymphoma. PACE CART19 consists of cells from a healthy donor that are genetically modified and designed to target your cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: leukemia,lymphoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female Age 18 or older Diagnosis of leukemia or lymphoma.

Updated on 04 Aug 2024. Study ID: 834589

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center